Literature DB >> 28956118

HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis.

Kyung-Eun Lee1, Sung-Eun Choi1, Haimuzi Xu1, Ji-Hyoun Kang1, Dong-Jin Park1, Shin-Seok Lee2.   

Abstract

We assessed potential predictors of sustained remission for 2 years according to the Disease Activity Score in 28 joints (DAS28)-CRP in patients with rheumatoid arthritis (RA). We obtained data for 290 RA outpatients, from July 2009 to September 2012. Sociodemographic data and answers to questionnaires were collected in face-to-face interviews. Remission was defined according to DAS28-CRP. Sustained remission was defined as meeting criteria for remission in the annual assessment for two consecutive years. Predictive factors of sustained remission according to DAS28-CRP were assessed by univariate and multivariate analyses. Of the 290 RA patients, the baseline remission level, according to DAS28-CRP, was 54.5%. During 2 years of follow-up, the sustained remission rate was 24.5%. RA patients who achieved sustained remission, according to DAS28-CRP, were younger, and had a shorter duration of symptoms, longer period of education, higher monthly income, lower Health Assessment Questionnaire (HAQ) score, lower physician global assessment, lower patient global assessment, lower patient pain assessment, and higher EQ-5D at baseline. Multivariate analyses showed that the baseline HAQ score was independently associated with sustained remission for 2 years according to DAS28-CRP (OR 0.298, 95% CI 0.115-0.770; p = 0.012). A lower HAQ score at baseline was an independent predictor of sustained remission at 2 years, according to DAS28-CRP. Thus, HAQ scores could be useful when stratifying patients according to risk for flare-ups in the clinic.

Entities:  

Keywords:  Physical function; Predictor; Remission; Rheumatoid arthritis

Mesh:

Year:  2017        PMID: 28956118     DOI: 10.1007/s00296-017-3833-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.

Authors:  Cheryl Barnabe; Joanne Homik; Susan G Barr; Liam Martin; Walter P Maksymowych
Journal:  J Rheumatol       Date:  2014-07-15       Impact factor: 4.666

2.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

Authors:  Shadi H Shahouri; Kaleb Michaud; Ted R Mikuls; Liron Caplan; Timothy S Shaver; James D Anderson; David N Weidensaul; Ruth E Busch; Shirley Wang; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2011-11

3.  How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

Authors:  Roy Fleischmann; Désirée van der Heijde; Andrew S Koenig; Ronald Pedersen; Annette Szumski; Lisa Marshall; Eustratios Bananis
Journal:  Ann Rheum Dis       Date:  2014-08-20       Impact factor: 19.103

4.  Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.

Authors:  Isabel Castrejón; Maxime Dougados; Bernard Combe; Bruno Fautrel; Francis Guillemin; Theodore Pincus
Journal:  J Rheumatol       Date:  2016-04-15       Impact factor: 4.666

5.  Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.

Authors:  B Combe; I Logeart; M C Belkacemi; S Dadoun; T Schaeverbeke; J P Daurès; M Dougados
Journal:  Ann Rheum Dis       Date:  2014-01-07       Impact factor: 19.103

6.  A reappraisal of HAQ disability in rheumatoid arthritis.

Authors:  F Wolfe
Journal:  Arthritis Rheum       Date:  2000-12

7.  Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS.

Authors:  Keeranur Jayakumar; Sam Norton; Josh Dixey; David James; Andrew Gough; Peter Williams; Peter Prouse; Adam Young
Journal:  Rheumatology (Oxford)       Date:  2011-11-16       Impact factor: 7.580

8.  The problem of rheumatoid arthritis disease activity and remission in clinical practice.

Authors:  Timothy S Shaver; James D Anderson; David N Weidensaul; Shadi H Shahouri; Shadi S Shahouri; Ruth E Busch; Ted R Mikuls; Kaleb Michaud; Frederick Wolfe
Journal:  J Rheumatol       Date:  2008-04-15       Impact factor: 4.666

9.  Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.

Authors:  L E Kristensen; M C Kapetanovic; A Gülfe; M Söderlin; T Saxne; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2008-03-03       Impact factor: 7.580

10.  Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.

Authors:  Helga Radner; Farideh Alasti; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2015-08-11       Impact factor: 5.156

View more
  5 in total

1.  In reply to the letter to the Editor, "HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis".

Authors:  Kyung-Eun Lee; Shin-Seok Lee
Journal:  Rheumatol Int       Date:  2017-10-17       Impact factor: 2.631

2.  HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis: methodological issues.

Authors:  Jie Weng; He Wu; Zhiyi Wang
Journal:  Rheumatol Int       Date:  2017-10-17       Impact factor: 2.631

3.  Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.

Authors:  Ennio G Favalli; Andrea Becciolini; Antonio Carletto; Fabrizio Conti; Giorgio Amato; Enrico Fusaro; Luca Quartuccio; Colin Gerard Egan; Andrea Lo Monaco; Maurizio Benucci; Fausto Salaffi; Angelo Semeraro; Simone Parisi; Fulvia Ceccarelli; Ilaria Piazza; Rosario Foti
Journal:  Rheumatol Int       Date:  2019-08-21       Impact factor: 2.631

4.  The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.

Authors:  Yoshiya Tanaka; Josef S Smolen; Heather Jones; Annette Szumski; Lisa Marshall; Paul Emery
Journal:  Arthritis Res Ther       Date:  2019-07-05       Impact factor: 5.156

5.  The Expansion of Myeloid-Derived Suppressor Cells Is Associated with Joint Inflammation in Rheumatic Patients with Arthritis.

Authors:  Junqing Zhu; Shixian Chen; Lisheng Wu; Ran Wang; Songyuan Zheng; Di Zhao; Xiangyang Wang; Juan Li
Journal:  Biomed Res Int       Date:  2018-06-26       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.